Watch for scammy stem cell therapies for COVID-19

“Scientists, regulators, and policymakers must guard against the proliferation of poorly designed, underpowered, and duplicative studies that are launched with undue haste because of the pandemic, but are unlikely to provide convincing, clinically meaningful safety and efficacy data,” says coauthor Leigh Turner, professor of [public health] at the University of California, Irvine.